Literature DB >> 31682644

Putting TDM knowledge into practice.

Alan C Moss1.   

Abstract

Keywords:  IBD clinical; infliximab; therapeutic drug monitoring

Year:  2019        PMID： 31682644      PMCID： PMC6788134          DOI： 10.1136/flgastro-2018-101159

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


× No keyword cloud information.
  5 in total

1.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Authors:  Niels Vande Casteele; Marc Ferrante; Gert Van Assche; Vera Ballet; Griet Compernolle; Kristel Van Steen; Steven Simoens; Paul Rutgeerts; Ann Gils; Séverine Vermeire
Journal:  Gastroenterology       Date:  2015-02-24       Impact factor: 22.682

Review 2.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

3.  Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study.

Authors:  Byron P Vaughn; Manuel Martinez-Vazquez; Vilas R Patwardhan; Alan C Moss; William J Sandborn; Adam S Cheifetz
Journal:  Inflamm Bowel Dis       Date:  2014-11       Impact factor: 5.325

Review 4.  Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease.

Authors:  Clare Moore; Gillian Corbett; Alan C Moss
Journal:  J Crohns Colitis       Date:  2016-01-13       Impact factor: 9.071

5.  Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.

Authors:  Luisa Guidi; Daniela Pugliese; Tommaso Panici Tonucci; Alexandra Berrino; Barbara Tolusso; Michele Basile; Laura Cantoro; Paola Balestrieri; Fortunata Civitelli; Lorenzo Bertani; Manuela Marzo; Carla Felice; Elisa Gremese; Francesco Costa; Franca Viola; Michele Cicala; Anna Kohn; Antonio Gasbarrini; Gian Lodovico Rapaccini; Matteo Ruggeri; Alessandro Armuzzi
Journal:  J Crohns Colitis       Date:  2018-08-29       Impact factor: 9.071
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.